olivLaw · European equity research
Scope Fluidics S.A. SCP.WA
Poland · GPW Warszawa · ISIN PLSCPFL00018 · Vertical: Listed companies from Poland
At the close of 06 Nov 2026, Scope Fluidics S.A. (SCP.WA) stock was 143.00 PLN (+1.13% on the day), with market capitalisation 389.9 m PLN, dividend yield 59.83%, beta 0.31, 52-week range 113.00–156.40 PLN.
Data as of · Source: ESEF annual reports and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 56.6
- strong (55–70)
- Bollinger (20, 2)
- 122.20 – 155.92
- in the upper half of the band · %B 0.62 · band width 24.2%
- SMA 50 / 200
- 131.97 / 132.44
- mixed trend
- MACD (12, 26, 9)
- 3.86 / 4.08
- MACD below signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | EURO STOXX 50 | vs EURO STOXX 50 | Vertical median | |
|---|---|---|---|---|
| 1 month | +12.6% | −0.6% | +13.2 pp | — |
| 3 months | +5.1% | −4.2% | +9.3 pp | — |
| 6 months | +18.2% | +4.3% | +13.8 pp | — |
| Year to date | +5.0% | +7.5% | −2.5 pp | — |
| 1 year | −6.4% | +9.9% | −16.3 pp | +5.9% |
| 3 years | −5.3% | +49.8% | −55.1 pp | +1.8% |
| 5 years | −10.6% | +42.8% | −53.5 pp | — |
Price returns, dividends excluded.
Quarterly results
ESEF annual reports carry no quarters: the results are annual (below).
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2021 | 2022 | 2023 |
|---|---|---|---|
| Revenue | 0 | 404.0 k | 516.0 k |
| Revenue YoY | unavailable | unavailable | +27.7% |
| Net income | -16.6 m | 318.5 m | -18.8 m |
| Net income YoY | unavailable | unavailable | −105.9% |
| Diluted EPS | -6.19 | 118.01 | -6.89 |
| Diluted EPS YoY | unavailable | unavailable | −105.8% |
| net % | unavailable | 78,833.9% | -3,640.5% |
| Free cash flow | unavailable | unavailable | unavailable |
Balance sheet & financial health
Fiscal year 2023 · 31 Dec 2023
- Cash
- 66.3 m PLN
- Financial debt
- unavailable PLN
- Net debt
- unavailable PLN
- Equity
- 80.9 m PLN
- Total assets
- 101.5 m PLN
- Debt / equity
- unavailable
- Current ratio
- 14.71x
- ROE
- -9.1%
- ROA
- -8.4%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (PLN)
Margins
Income statement · PLN
| Line | 2021 | 2022 | 2023 | Source (latest year) |
|---|---|---|---|---|
| Revenue | 0 | 404.0 k | 516.0 k | esef· 01 May 2024verified |
| Operating income | -10.2 m | 393.3 m | -28.7 m | esef· 01 May 2024verified |
| Depreciation & amortisation | 414.0 k | 641.0 k | 1.1 m | esef· 01 May 2024verified |
| EBITDA | -9.8 m ≈ | 394.0 m ≈ | -27.6 m ≈ | esef· 01 May 2024derived |
| Interest expense | 1.5 m | 10.8 m | 857.0 k | esef· 01 May 2024verified |
| Pre-tax income | -11.7 m | 395.1 m | -18.7 m | esef· 01 May 2024verified |
| Income tax | 1.0 k | 69.1 m | 129.0 k | esef· 01 May 2024verified |
| Net income | -16.6 m | 318.5 m | -18.8 m | esef· 01 May 2024verified |
| Diluted EPS | -6.19 | 118.01 | -6.89 | esef· 01 May 2024verified |
| Dividend per share | — | 0.00 | 85.55 | esef· 01 May 2024derived |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · PLN
| Line | 2021 | 2022 | 2023 | Source (latest year) |
|---|---|---|---|---|
| Cash | 18.1 m | 331.6 m | 66.3 m | esef· 01 May 2024verified |
| Receivables | 1.2 m | 4.4 m | 2.6 m | esef· 01 May 2024verified |
| Inventories | 287.0 k | 673.0 k | 710.0 k | esef· 01 May 2024verified |
| Current assets | 45.7 m | 336.7 m | 90.5 m | esef· 01 May 2024verified |
| Property, plant & equipment, net | 409.0 k | 322.0 k | 1.9 m | esef· 01 May 2024verified |
| Intangibles (excl. goodwill) | 74.0 k | 21.0 k | 107.0 k | esef· 01 May 2024verified |
| Total assets | 52.7 m | 346.2 m | 101.5 m | esef· 01 May 2024verified |
| Current liabilities | 28.7 m | 4.9 m | 6.2 m | esef· 01 May 2024verified |
| Total liabilities | 46.0 m | 13.2 m | 20.6 m | esef· 01 May 2024verified |
| Equity | 6.7 m | 333.0 m | 80.9 m | esef· 01 May 2024verified |
| Shares outstanding at year end | 2.7 m | 2.7 m | 2.7 m | esef· 01 May 2024derived |
Cash flow · PLN
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 4 of at least 6
- score weight coverage: 22.9% of at least 60%
A scoring methodology on indicators and valuation, not investment advice.
Closing price
06 Nov 2026Source: olivLaw, closing series
Market cap: 389.9 m PLN
Key indicators
Coverage and freshness
The data is older than the freshness threshold.
Score by group
23% · Insufficient data
Estimated value range
unavailable — no valuation assumptions for the reporting currency
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
Assumptions (illustrative, editorial)
- Risk-free rate
- 6.5%
- Equity risk premium
- 6.0%
- Beta (default)
- 1.00
- Cost of equity
- 12.5%
- Terminal growth
- 3.0%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 4 of at least 6; score weight coverage: 22.9% of at least 60%
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | -3,640.5% | 3 (vs peers) | 27% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | -33.5x | 0 (on a fixed band) | 27% |
| Current ratio · Balance sheet | 14.7x | 100 (on a fixed band) | 18% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | unavailable | unavailable | — |
| Shareholder yield (distributions) · Returns | 59.8% | 100 (on a fixed band) | 27% |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet40/100 · 2/3 factors with a value
- Growth· partialunavailable · 0/2 factors with a value
- Quality· partial3/100 · 1/3 factors with a value
- Returns· partial100/100 · 1/2 factors with a value
- Valuation· partialunavailable · 0/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
SCOPE FLUIDICS S.A. (SCP.WA). Latest full fiscal year: 2023; data up to 2023-12-31.
Figures computed from the financial statements: revenue 516.0 k PLN in 2023; YoY growth 27.7%; net margin -3,640.5%; ROE -9.1%.
The estimated value range is 839.25–1,036.72 PLN per share (median of 1 methods, agreement: single method); assumptions are illustrative. Against the central value of 927.59 PLN, the price of 143.00 PLN leaves a potential of 548.7% (value / price − 1) and a margin of safety of 84.6% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
Insufficient data for a verdict (indicators available: 4 of at least 6; score weight coverage: 22.9% of at least 60%).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Current ratio: 14.7x
- Shareholder yield (distributions): 59.8%
- The price is below the estimated value range
What contradicts it
- Net margin: -3,640.5%
- Interest coverage: -33.5x
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, Revenue CAGR 3Y, EPS CAGR 3Y, Net debt / EBITDA, P/E (TTM), EV/EBITDA, FCF yield, Payout ratio (FCF).
Versus the vertical median
Listed companies from Poland · same country · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| ACP.WAAsseco Poland S.A. | 19.0 bn | 37.8 | 7.8% | 2.9% | +19.8% | +18% / +199% |
| BDX.WABudimex Spółka Akcyjna | 18.9 bn | 35.3 | 41.5% | 6.2% | +8.9% | +18% / +33% |
| BFT.WABenefit Systems Spółka Akcyjna | 18.1 bn | 130.7 | 20.8% | 7.2% | +99.9% | +74% / +221% |
| ASE.WAAsseco South Eastern Europe Spółka Akcyjna | 3.7 bn | 19.6 | 18.1% | 12.0% | +36.5% | +6% / +50% |
| 1AT.WAAtal Spółka Akcyjna | 2.3 bn | 6.4 | 29.8% | 22.2% | −1.3% | +7% / +8% |
| ATT.WAGrupa Azoty Spółka Akcyjna | 1.6 bn | — | -37.9% | -20.8% | −45.1% | −15% / −26% |
| ARH.WAArchicom Spółka Akcyjna | 1.3 bn | 12.1 | 15.9% | 22.1% | −21.6% | +13% / +88% |
| ACT.WAAction S.A. | 999.4 m | 27.2 | 8.3% | 1.5% | +6.1% | +71% / +171% |
| BRS.WABoryszew Spółka Akcyjna | 874.1 m | 8.2 | 6.3% | 1.6% | +8.4% | −25% / −28% |
| AGO.WAAgora Spółka Akcyjna | 588.0 m | — | -14.2% | -9.2% | +15.2% | +37% / +18% |
| AMB.WAAmbra S.A. | 462.9 m | 7.5 | 16.4% | 7.0% | +12.9% | +4% / −33% |
| SCP.WAScope Fluidics S.A. | 389.9 m | — | -9.1% | -3,640.5% | +27.7% | −3% / −21% |
| ATC.WAArctic Paper Spółka Akcyjna | 344.7 m | 1.4 | 16.3% | 7.0% | −27.5% | −40% / −75% |
| ATG.WA"atm Grupa Spółka Akcyjna" | 298.5 m | 11.0 | 8.9% | 11.6% | −22.0% | −11% / +2% |
| ART.WAArtifex Mundi S.A. | 229.7 m | 17.7 | 35.7% | 33.3% | +51.9% | +48% / +14% |
| APN.WAAPLISENS Spółka Akcyjna | 192.4 m | 9.4 | 11.4% | 13.8% | +21.8% | −2% / −22% |
| ALI.WAALTUS Spolka Akcyjna | 158.1 m | 17.3 | 7.9% | 16.9% | +30.3% | +38% / +52% |
| BMC.WABumech Spółka Akcyjna | 156.9 m | — | -3.4% | -3.9% | −40.0% | −36% / −49% |
| BBT.WABoomBit Spółka Akcyjna | 71.9 m | 4.5 | 20.7% | 6.4% | −16.5% | −18% / −56% |
| BBD.WABbi Development S.A. | 54.1 m | 1.1 | 36.0% | 208.3% | +50.2% | +1% / +9% |
| ALG.WAAll in! Games Spółka Akcyjna | 39.6 m | — | — | -156.9% | −72.2% | −27% / −56% |
| BMX.WABioMaxima Spółka Akcyjna | 36.3 m | 62.0 | 1.2% | 1.3% | −67.5% | −31% / −46% |
| 06N.WAMagna Polonia Spółka Akcyjna | 31.1 m | 0.5 | 115.4% | 964.7% | +13.0% | −29% / −43% |
| BCM.WABETACOM Spółka Akcyjna | 26.3 m | 17.3 | 8.0% | 0.9% | +21.3% | +6% / +2% |
| AWM.WAAirway Medix Spółka Akcyjna | 13.8 m | — | -25.8% | -117,400.0% | −97.7% | −26% / −45% |
1- and 3-year price returns: for SCP.WA from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (PLN)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
The qualitative analysis has not been written for this company yet.
Products, market & competition
The qualitative analysis has not been written for this company yet.
News & filings
In the press
No news in our archive over the last 180 days.
Annual reports (ESEF)
- Annual report 202301 May 2024
- Annual report 202301 May 2024
- Annual report 202202 May 2023
Figures computed by olivLaw from ESEF annual reports and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.